Guardant Health Inc (NASDAQ:GH) – Leerink Swann issued their Q3 2018 earnings estimates for Guardant Health in a research report issued on Monday, October 29th. Leerink Swann analyst P. Souda anticipates that the company will post earnings of ($0.28) per share for the quarter. Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Guardant Health’s Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($1.03) EPS, Q1 2019 earnings at ($0.30) EPS, Q2 2019 earnings at ($0.32) EPS, Q3 2019 earnings at ($0.33) EPS, Q4 2019 earnings at ($0.34) EPS, FY2019 earnings at ($1.29) EPS, FY2020 earnings at ($0.92) EPS and FY2021 earnings at ($0.50) EPS.
A number of other equities analysts have also recently commented on the company. JPMorgan Chase & Co. assumed coverage on Guardant Health in a report on Monday. They issued an “overweight” rating and a $42.00 target price on the stock. Bank of America assumed coverage on Guardant Health in a report on Monday. They issued a “neutral” rating and a $37.00 target price on the stock. Cowen assumed coverage on Guardant Health in a report on Monday. They issued an “outperform” rating on the stock. Finally, William Blair assumed coverage on Guardant Health in a report on Monday. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $39.50.
Guardant Health Company Profile
Guardant Health, Inc is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
See Also: What are Institutional Investors?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.